

# David Drobne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490398/publications.pdf>

Version: 2024-02-01

6  
papers

139  
citations

1477746

6  
h-index

1872312

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

210  
citing authors

#	ARTICLE	IF	CITATIONS
1	Success and safety of high infliximab trough levels in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2018, 53, 940-946.	0.6	38
2	Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 880-889.	1.9	32
3	Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. Clinical Gastroenterology and Hepatology, 2021, 19, 111-118.e10.	2.4	28
4	Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 741-749.	1.6	17
5	Dose optimisation for Loss of Response to Vedolizumab: Pharmacokinetics and Immune Mechanisms. Journal of Crohn's and Colitis, 2021, 15, 1707-1719.	0.6	16
6	Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics, 2021, 13, 1587.	2.0	8